There are two streams of research in the area of Infectious Diseases and Hepatitis at St Vincent’s Hospital Sydney.
Therapeutic and Vaccine Research Program
The Therapeutic and Vaccine Research Program (TVRP) led by Professor Matthews conducts clinical trials that assess real-world effectiveness of new treatments and therapeutic approaches. The program also supports laboratory studies to better understand the underlying causes of diseases and mechanisms of treatment response.
Studies led by TVRP have been instrumental in defining the current standard of treatment for HIV globally. TVRP are leaders in conducting trials that focus on optimising HIV treatments in settings with limited resources and on reducing the long-term health impacts of HIV worldwide.
TVRP provides global leadership via its role as an International Coordinating Centre for the STRIVE (Strategies and Treatments for Respiratory Infections and Viral Emergencies) network, a major international collaboration for the conduct of large clinical trials in HIV and other viruses, which has more than 300 sites in 30 countries. As part of this network, TVRP functions as the Sydney Coordinating Centre for sites in Australia, Singapore, S Korea, Japan, Thailand, India, Nigeria and Argentina.
Contact: info@kirby.unsw.edu.au
+61 (2) 9385 0900
Viral Hepatitis Clinical Research
The Viral Hepatitis Service at St Vincent’s Hospital was established by Professor Dore in 1999, who has guided its development into one of the leading hepatitis C treatment services in Australia and internationally. The service has a particular focus on marginalised populations, including people who inject drugs and homeless persons.
Key areas of research include the treatment of acute and chronic hepatitis C, particularly in the setting of injecting drug use. Research also focuses on HIV and hepatitis C virus (HCV) coinfection, and HIV and hepatitis B virus (HBV) coinfection.
An important emerging focus for the program involves research into simplified approaches to HCV diagnostics and linkage to treatment options, with future directions including investigating strategies to enhance HCV management in resource-limited settings. The team is also working on several projects investigating the use of HCV treatments for hepatitis C prevention and elimination of the virus. The aim in Australia and internationally is to eliminate viral hepatitis by 2030.
Contact: info@kirby.unsw.edu.au
+61 (2) 9385 0900